RHBC
TCRT icon

R.H. Bluestein & Co’s Alaunos Therapeutics TCRT Stock Holding History

R.H. Bluestein & Co’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-80
Closed -$76K – 334
2017
Q1 		$76K Hold
80
– – ﹤0.01% 319
2016
Q4 		$64K Hold
80
– – ﹤0.01% 303
2016
Q3 		$68K Hold
80
– – ﹤0.01% 294
2016
Q2 		$66K Buy
80
+8
+11% +$8.71K 0.01% 287
2016
Q1 		$80K Hold
72
– – 0.01% 285
2015
Q4 		$90K Hold
72
– – 0.01% 290
2015
Q3 		$97K Hold
72
– – 0.01% 300
2015
Q2 		$130K Buy
72
+5
+7% +$7.76K 0.01% 321
2015
Q1 		$108K Buy
+67
New +$99.3K 0.01% 335

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

R.H. Bluestein & Co's TCRT Position: Q2 2017 in Review

R.H. Bluestein & Co sold out of Alaunos Therapeutics (TCRT) in Q2 2017, closing a stake of 80 shares — an estimated $76K sold.

R.H. Bluestein & Co first reported a position in TCRT in Q1 2015 and held it in 9 quarters. The position peaked at $130K in Q2 2015. 122 funds tracked by Wall St. Rank hold TCRT as of Q2 2017.

  • R.H. Bluestein & Co reported no remaining Alaunos Therapeutics position as of Q2 2017 after selling out during the quarter.
  • R.H. Bluestein & Co sold 80 Alaunos Therapeutics shares in Q2 2017, an estimated $76K.
  • R.H. Bluestein & Co first reported a position in Alaunos Therapeutics in Q1 2015 and held it in 9 quarters.
  • R.H. Bluestein & Co's Alaunos Therapeutics position peaked at $130K in Q2 2015.
  • 122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2017.

Based on R.H. Bluestein & Co's 13F filing for Q2 2017, filed 11 Aug 2017.